Enrique Roberto Soriano

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8685693/publications.pdf

Version: 2024-02-01

174 papers

5,578 citations

147801 31 h-index 70 g-index

188 all docs 188 docs citations

188 times ranked 5678 citing authors

#	Article	IF	CITATIONS
1	Correspondence on â€~No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related †physician-reported spondylitis'?'. Annals of the Rheumatic Diseases, 2023, 82, e187-e187.	0.9	3
2	Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis. Annals of the Rheumatic Diseases, 2022, 81, 74-79.	0.9	55
3	Rheumatology Training in Latin America. Journal of Clinical Rheumatology, 2022, 28, e440-e443.	0.9	3
4	Impact of COVID-19 pandemic on patients with rheumatic diseases in Latin America. Rheumatology International, 2022, 42, 41-49.	3.0	18
5	Ultrasound-detected tenosynovitis as a risk factor for flares in rheumatoid arthritis patients in clinical remission. Clinical Rheumatology, 2022, , $1.$	2.2	1
6	GRAPPA Treatment Recommendations: 2021 Update. Journal of Rheumatology, 2022, , jrheum.211331.	2.0	12
7	Current Status and Future Challenges in the Treatment of Rheumatic Diseases. Frontiers in Drug Safety and Regulation, 2022, 2, .	1.8	O
8	Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52ÂWeeks: Data from Three PhaseÂIII Randomised Controlled Trials. Advances in Therapy, 2022, 39, 2806-2819.	2.9	4
9	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nature Reviews Rheumatology, 2022, 18, 465-479.	8.0	182
10	LARS study: Latin American rheumatologist survey. Clinical Rheumatology, 2021, 40, 377-387.	2.2	4
11	Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis. JAMA Dermatology, 2021, 157, 43.	4.1	43
12	Design of an algorithm for the diagnostic approach of patients with joint pain. Clinical Rheumatology, 2021, 40, 1581-1591.	2.2	3
13	A longitudinal multiethnic study of biomarkers in systemic lupus erythematosus: Launching the GLADEL 2.0 Study Group. Lupus, 2021, 30, 630-640.	1.6	2
14	Current status of the rheumatologists' workforce in Latin America: a PANLAR collaborative study. Clinical Rheumatology, 2021, 40, 2913-2920.	2.2	22
15	Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-na \tilde{A} -ve or TNF \hat{I} ± inhibitor-experienced. RMD Open, 2021, 7, e001457.	3.8	41
16	GRAPPA Treatment Recommendations: An Update From the 2020 GRAPPA Annual Meeting. Journal of Rheumatology, 2021, , jrheum.201681.	2.0	14
17	Effect of Tocilizumab on LDL and HDL Characteristics in Patients with Rheumatoid Arthritis. An Observational Study. Rheumatology and Therapy, 2021, 8, 803-815.	2.3	13
18	Osteoporotic fractures in rheumatoid arthritis patients in Argentina: a matched retrospective cohort study. Advances in Rheumatology, 2021, 61, 21.	1.7	4

#	Article	IF	Citations
19	OP0229â€THE GROUP FOR RESEARCH AND ASSESSMENT OF PSORIASIS AND PSORIATIC ARTHRITIS (GRAPPA) TREATMENT RECOMMENDATIONS 2021. Annals of the Rheumatic Diseases, 2021, 80, 139-140.	0.9	19
20	POS0984â€PREVALENCE OF AXIAL SPONDYLOARTHRITIS AMONG YOUNG PEOPLE CONSULTING BECAUSE OF CHRONIC LOW BACK PAIN IN A UNIVERSITY HOSPITAL IN ARGENTINA. Annals of the Rheumatic Diseases, 2021, 80, 759-760.	0.9	0
21	POS1188â€COVID-19 IN PATIENTS WITH RHEUMATIC DISEASES: COMPARISON OF DATA FROM THE ARGENTING REGISTRY (SAR-COVID), WITH THE LATIN AMERICAN AND GLOBAL REGISTRY (GLOBAL RHEUMATOLOGY) Tj ETQq1		3 b 4 rgBT /○\
22	POS0302â€BURNOUT IN RHEUMATOLOGISTS IN LATIN AMERICA. Annals of the Rheumatic Diseases, 2021, 80, 376.2-377.	0.9	0
23	ABO214â€SURVIVAL, EFFICACY AND SAFETY OF GOLIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND SPONDYLOARTHRITIS: DATA FROM AN ARGENTINEAN COHORT. Annals of the Rheumatic Diseases, 2021, 80, 1133-1134.	0.9	0
24	AB0529â€CHARACTERIZATION OF REMISSION IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH UPADACITINIB: POST-HOC ANALYSIS FROM TWO PHASE 3 TRIALS. Annals of the Rheumatic Diseases, 2021, 80, 1294-1295.	0.9	0
25	Impact of COVID-19 Pandemic on Rheumatology Practice in Latin America. Journal of Rheumatology, 2021, 48, 1616-1622.	2.0	12
26	Health systems strengthening to arrest the global disability burden: empirical development of prioritised components for a global strategy for improving musculoskeletal health. BMJ Global Health, 2021, 6, e006045.	4.7	26
27	Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1. Rheumatology and Therapy, 2021, 8, 1789-1808.	2.3	14
28	Report on the Second PANLAR Review Course in Rheumatology. Journal of Clinical Rheumatology, 2020, 26, 33-36.	0.9	0
29	Rheumatoid Arthritis Patient's Journey. Journal of Clinical Rheumatology, 2020, 26, S148-S152.	0.9	15
30	Improvement in the capacity of HDL to acquire free cholesterol associated with anti-inflammatory actions of tofacitinib in patients with RA. Atherosclerosis, 2020, 315, e152-e153.	0.8	0
31	Are superantigens the cause of cytokine storm and viral sepsis in severe COVIDâ€19? Observations and hypothesis. Scandinavian Journal of Immunology, 2020, 92, e12944.	2.7	19
32	Performance of Ultrasonography Compared to Conventional Radiography for the Diagnosis of Osteoarthritis in Patients With Knee Pain. Frontiers in Medicine, 2020, 7, 319.	2.6	6
33	Fragility fractures in psoriatic arthritis patients: a matched retrospective cohort study. Clinical Rheumatology, 2020, 39, 3685-3691.	2.2	4
34	Effectiveness of the use of an algorithm in the diagnostic approach of joint pain patients by primary care physicians. Rheumatology International, 2020, 40, 1857-1864.	3.0	0
35	Experience of a Performance-Based Risk-Sharing Arrangement for the Treatment of Rheumatoid Arthritis With Certolizumab Pegol. Value in Health Regional Issues, 2020, 21, 201-204.	1.2	2
36	Clinical features, damage accrual, and survival in patients with familial systemic lupus erythematosus: data from a multi-ethnic, multinational Latin American lupus cohort. Lupus, 2020, 29, 1140-1145.	1.6	1

#	Article	IF	CITATIONS
37	Levels of satisfaction with rheumatoid arthritis treatment and associated alignment between physicians and patients across Latin America. Clinical Rheumatology, 2020, 39, 1813-1822.	2.2	4
38	Physician-patient alignment in satisfaction with psoriatic arthritis treatment in Latin America. Clinical Rheumatology, 2020, 39, 1859-1869.	2.2	14
39	Applying the 2019 EULAR/ACR lupus criteria to patients from an established cohort: a Latin American perspective. RMD Open, 2020, 6, e001097.	3.8	26
40	Predictors of renal damage in systemic lupus erythematous patients: data from a multiethnic, multinational Latin American lupus cohort (GLADEL). RMD Open, 2020, 6, e001299.	3.8	16
41	SATO144â€DOES POLYPHARMACY IN RHEUMATOID ARTHRITIS PATIENTS AFFECT THE TREAT TO TARGET STRATEGY?. Annals of the Rheumatic Diseases, 2020, 79, 1010.1-1010.	0.9	0
42	GRAPPA Treatment Recommendations: Updates and Methods. Journal of Rheumatology, 2020, 96, 41-45.	2.0	12
43	AB0831â€COMPARISON OF DIFFERENT REMISSION INDICES IN PATIENTS WITH PSORIATIC ARTHRITIS: A POST HOC ANALYSIS OF DATA FROM PHASE 3 TOFACITINIB STUDIES. Annals of the Rheumatic Diseases, 2020, 79, 1720-1721.	0.9	0
44	SATO426â€CAN BIOLOGICS "PREVENT―THE DEVELOPMENT OF PSORIATIC ARTHRITIS IN PSORIASIS PATIENDATA FROM A LARGE UNIVERSITY HOSPITAL COHORT IN ARGENTINA. Annals of the Rheumatic Diseases, 2020, 79, 1167-1168.	NTS? 0.9	1
45	FRIO332â€EVALUATION OF THE INDIVIDUAL COMPONENTS OF ACR50+PASI100 AND MDA AT WEEK 24 FROM SPIRIT-H2H TRIAL COMPARING THE EFFICACY AND SAFETY OF IXE VERSUS ADA IN PATIENTS WITH PSA NAÃVE TO BDMARDS. Annals of the Rheumatic Diseases, 2020, 79, 758.1-758.	THE 0.9	0
46	AB1270â€RHEUMATOLOGY WORKFORCE IN LATIN AMERICA: TRAINING AND CURRENT STATUS. Annals of the Rheumatic Diseases, 2020, 79, 1926.1-1926.	0.9	0
47	Management of non-renal non-neurologic persistent lupus activity in real world patients from Argentina. Lupus, 2019, 28, 1167-1173.	1.6	1
48	Incidence of cancer in a cohort of patients with primary Sj \tilde{A} ¶gren syndrome in Argentina. Rheumatology International, 2019, 39, 1697-1702.	3.0	18
49	Clinical predictors of remission and low disease activity in Latin American early rheumatoid arthritis: data from the GLADAR cohort. Clinical Rheumatology, 2019, 38, 2737-2746.	2.2	10
50	Changing rate of serious infections in biologic-exposed rheumatoid arthritis patients. Data from South American registries BIOBADABRASIL and BIOBADASAR. Clinical Rheumatology, 2019, 38, 2129-2139.	2.2	8
51	Causes of fetal third-degree atrioventricular block and use of hydroxychloroquine in pregnant women with Ro/La antibodies. Clinical Rheumatology, 2019, 38, 2211-2217.	2.2	9
52	PANLAR consensus statement on biosimilars. Clinical Rheumatology, 2019, 38, 1485-1496.	2.2	9
53	Incidence and prevalence of granulomatosis with polyangiitis and microscopic polyangiitis in health management organization in Argentina: a 15-year study. Clinical Rheumatology, 2019, 38, 1935-1940.	2.2	14
54	AB1228â€ACCESS TO RHEUMATOLOGIC TREATMENTS AND AUTOIMMUNE CONDITIONS IN LATIN AMERICA. , 2019, , .		0

#	Article	IF	Citations
55	Interventions on Modifiable Risk Factors for the Development of Psoriatic Arthritis. Current Treatment Options in Rheumatology, 2019, 5, 313-325.	1.4	4
56	Value of Color Doppler Ultrasound Assessment of Sacroiliac Joints in Patients with Inflammatory Low Back Pain. Journal of Rheumatology, 2019, 46, 694-700.	2.0	4
57	Spanish Validation of the GEPARD Questionnaire for the Detection of Psoriatic Arthritis in Argentinian Patients with Psoriasis. Dermatology, 2019, 235, 101-106.	2.1	1
58	Towards standardized patient reported physical function outcome reporting: linking ten commonly used questionnaires to a common metric. Quality of Life Research, 2019, 28, 187-197.	3.1	14
59	International Consortium for Health Outcome Measurement Set of Outcomes That Matter to People Living With Inflammatory Arthritis: Consensus From an International Working Group. Arthritis Care and Research, 2019, 71, 1556-1565.	3.4	43
60	Response to: ‴Clinical evidence guidelines in systemic lupus erythematosus: revaluation' by Scheinberg. Annals of the Rheumatic Diseases, 2019, 78, e120-e120.	0.9	1
61	A Consensus Position Paper From REAL-PANLAR Group About the Methodological Approach for the Accreditation Process of Centers of Excellence in Rheumatoid Arthritis in Latin America. Journal of Clinical Rheumatology, 2019, 25, 54-58.	0.9	7
62	Evaluation of Learned Helplessness, Perceived Self-efficacy, and Functional Capacity in Patients With Fibromyalgia and Rheumatoid Arthritis. Journal of Clinical Rheumatology, 2019, 25, 65-68.	0.9	16
63	Best-practice Indicators in Psoriatic Disease Care. Journal of Rheumatology, 2019, 95, 38-45.	2.0	5
64	Certolizumab pegol in a heterogeneous population of patients with moderate-to-severe rheumatoid arthritis. Future Science OA, 2018, 4, FSO289.	1.9	5
65	Valor de la ecografÃa con Doppler de poder en pacientes con artritis reumatoide en remisión clÃnica: ¿reclasificación de la actividad de la enfermedad?. ReumatologÃa ClÃnica, 2018, 14, 202-206.	0.5	2
66	Remission in psoriatic arthritis—where are we now?. Rheumatology, 2018, 57, 1321-1331.	1.9	16
67	Psoriatic arthritis: new evidence for old concepts. Current Opinion in Rheumatology, 2018, 30, 87-93.	4.3	2
68	Therapeutic Guidelines for Latin American Lupus Patients. Journal of Clinical Rheumatology, 2018, 24, 41-44.	0.9	7
69	CNTO6785, a Fully Human Antiinterleukin 17 Monoclonal Antibody, in Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: A Randomized, Placebo-controlled, Phase II, Dose-ranging Study. Journal of Rheumatology, 2018, 45, 22-31.	2.0	17
70	CS-08â€Effect of antimalarials over the different domains of the damage index in latin american SLE patients. , 2018, , .		0
71	FRIO099â€Liver enzyme abnormalities after tofacitinib treatment in patients with hepatic steatosis from the rheumatoid arthritis, psoriatic arthritis and psoriasis clinical programmes. , 2018, , .		O
72	FRIO709-HPRâ€Levels of satisfaction with psoriatic arthritis (PSA) treatment and associated alignment between rheumatologists and their patients across latin america. , 2018, , .		1

#	Article	IF	CITATIONS
73	Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease. Arthritis Research and Therapy, 2018, 20, 242.	3.5	24
74	Spotlight on certolizumab pegol in the treatment of axial spondyloarthritis: efficacy, safety and place in therapy. Open Access Rheumatology: Research and Reviews, 2018, Volume 10, 33-41.	1.6	7
75	First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, <i>Grupo Latino Americano de Estudio del) Tj ETQq1 1 0.7 Diseases. 2018. 77. 1549-1557.</i>	784314 rg 0.9	BT/Overlock
76	The Value of Power Doppler Ultrasound in Patients With Rheumatoid Arthritis in Clinical Remission: Reclassifying Disease Activity?. ReumatologÃa ClÃnica (English Edition), 2018, 14, 202-206.	0.3	4
77	THU0323â€Tofacitinib improves composite endpoint measures of disease in patients with psoriatic arthritis., 2018,,.		0
78	SAT0345â€Quality indicators in the care of psoriatic arthritis. , 2018, , .		0
79	FRIO668 Item response theory to standardize patient reported physical function outcomes; linking 10 commonly used questionnaires to a common metric. , 2018, , .		0
80	Early discoid lupus erythematosus protects against renal disease in patients with systemic lupus erythematosus: longitudinal data from a large Latin American cohort. Lupus, 2017, 26, 73-83.	1.6	8
81	Factors predictive of high disease activity early in the course of SLE in patients from a Latin-American cohort. Seminars in Arthritis and Rheumatism, 2017, 47, 199-203.	3.4	11
82	Ultrasound entheseal abnormalities at the distal interphalangeal joints and clinical nail involvement in patients with psoriasis and psoriatic arthritis, supporting the nail-enthesitis theory. Seminars in Arthritis and Rheumatism, 2017, 47, 338-342.	3.4	43
83	Utility of Power Doppler Ultrasound–detected Synovitis for the Prediction of Short-term Flare in Psoriatic Patients with Arthritis in Clinical Remission. Journal of Rheumatology, 2017, 44, 1018-1023.	2.0	19
84	Defining Quality of Rheumatolgic Care: Argentina. Journal of Clinical Rheumatology, 2017, 23, 207-208.	0.9	2
85	192â€Protective effect of antimalarials on the risk of damage accrual in systemic lupus erythematosus. , 2017, , .		0
86	AB0516â€Incidence of cancer in a cohort of patients with primary sjÖgren syndrome. , 2017, , .		0
87	Enthesitis: from pathophysiology to treatment. Nature Reviews Rheumatology, 2017, 13, 731-741.	8.0	316
88	Complement levels and risk of organ involvement in patients with systemic lupus erythematosus. Lupus Science and Medicine, 2017, 4, e000209.	2.7	17
89	Evaluation of learned helplessness, self-efficacy and disease activity, functional capacity and pain in Argentinian patients with rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2017, 46, 17-21.	1.1	14
90	FRIO483 Work capacity and quality of life in a cohort of patients with early psoriatic arthritis in argentina. , 2017, , .		0

#	Article	lF	Citations
91	AB0194â€Journey of a patient with rheumatoid arthritis: delay in diagnosis and treatment. , 2017, , .		O
92	FRIO601â€Hyperferritinemic syndrome in a general universitary hospital. , 2017, , .		0
93	SAT0427â€Asas health index: validity and reliability in argentinean patients with spondyloarthritis. , 2017,		1
94	Systematic and progressive implementation of the centers of excellence for rheumatoid arthritis: a methodological proposal. Clinical Rheumatology, 2017, 36, 2855-2858.	2.2	5
95	AB0789â€The psoriatic arthritis patient's journey: special emphasis on diagnosis and treatment delays. , 2017, , .		O
96	ANCA-associated pauci-immune glomerulonephritis: always pauci-immune?. Clinical and Experimental Rheumatology, 2017, 35 Suppl 103, 55-58.	0.8	9
97	An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy. Open Access Rheumatology: Research and Reviews, 2016, 8, 37.	1.6	8
98	Does a Simplified 6-Joint Ultrasound Index Correlate Well Enough With the 28-Joint Disease Activity Score to Be Used in Clinical Practice?. Journal of Clinical Rheumatology, 2016, 22, 179-183.	0.9	8
99	Incidence and Prevalence of Rheumatoid Arthritis in a Health Management Organization in Argentina: A 15-year Study. Journal of Rheumatology, 2016, 43, 1306-1311.	2.0	28
100	SATO123â€Radiographic Severity of Rheumatoid Arthritis in Latin American Patients: Results from The Gladar Cohort. Annals of the Rheumatic Diseases, 2016, 75, 709.3-710.	0.9	O
101	Prevalence of biologics monotherapy in a cohort of patients with Rheumatoid Arthritis in daily clinical practice. BMC Musculoskeletal Disorders, 2016, 17, 110.	1.9	12
102	Associations between disease activity, markers of HDL functionality and arterial stiffness in patients with rheumatoid arthritis. Atherosclerosis, 2016, 251, 438-444.	0.8	29
103	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis and Rheumatology, 2016, 68, 1060-1071.	5.6	726
104	Patients with Psoriatic Arthritis Fulfilling the Minimal Disease Activity Criteria Do Not Have Swollen and Tender Joints, but Have Active Skin. Journal of Rheumatology, 2016, 43, 907-910.	2.0	15
105	Knee effusion: ultrasound as a useful tool for the detection of calcium pyrophosphate crystals. Clinical Rheumatology, 2016, 35, 1087-1091.	2.2	11
106	Oral Non-biologic Therapies and Non-pharmacological Therapies in PsA. , 2016, , 267-279.		0
107	REAL-PANLAR Project for the Implementation and Accreditation of Centers of Excellence in Rheumatoid Arthritis Throughout Latin America. Journal of Clinical Rheumatology, 2015, 21, 175-180.	0.9	25
108	THU0145â€Low Agreement Between Clinical Practice and Centralized Lecture Using the Sharp/Van DER Heijde Score in Patients with Early RA. Results from the Gladar Multinational Cohort. Annals of the Rheumatic Diseases, 2015, 74, 246.1-246.	0.9	0

#	Article	IF	Citations
109	AB0802â€Use of Caspar and ASAS Classification Criteria for Peripheral Involvement in Patients Diagnosed with Psoriatic Arthritis in the Region of Murcia (Spain). Annals of the Rheumatic Diseases, 2015, 74, 1167.3-1167.	0.9	1
110	New treatment paradigms in psoriatic arthritis. Current Opinion in Rheumatology, 2015, 27, 99-106.	4.3	16
111	Late-onset systemic lupus erythematosus in Latin Americans: a distinct subgroup?. Lupus, 2015, 24, 788-795.	1.6	39
112	Work disability is related to the presence of arthritis and not to a specific diagnosis. Results from a large early arthritis cohort in Argentina. Clinical Rheumatology, 2015, 34, 929-933.	2.2	13
113	Effects of cigarette smoking on early arthritis: a cross-sectional study—data from the Argentine Consortium for Early Arthritis (CONAART). Rheumatology International, 2015, 35, 855-859.	3.0	10
114	The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: data from a multiethnic Latin American cohort. Annals of the Rheumatic Diseases, 2015, 74, 1019-1023.	0.9	100
115	Ultrasound Evaluation of the Greater Trochanter Pain Syndrome. Journal of Clinical Rheumatology, 2015, 21, 99-101.	0.9	9
116	Management of Psoriatic Arthritis. Rheumatic Disease Clinics of North America, 2015, 41, 711-722.	1.9	4
117	Proper management of rheumatoid arthritis in Latin America. What the guidelines say?. Clinical Rheumatology, 2015, 34, 51-55.	2.2	18
118	Defining Remission in Psoriatic Arthritis: Are We Getting Closer?. Journal of Rheumatology, 2015, 42, 907-908.	2.0	10
119	Responsiveness to therapy change of a global ultrasound assessment in spondyloarthritis patients. Clinical Rheumatology, 2015, 34, 125-132.	2.2	10
120	Value of repeat biopsy in lupus nephritis flares. Lupus Science and Medicine, 2014, 1, e000004.	2.7	35
121	AB1075â€Argentinian Register of BIOLOGICS Treatments (BIOBADASAR). Results. Annals of the Rheumatic Diseases, 2014, 73, 1156.3-1157.	0.9	1
122	Pharmacologic treatment of psoriatic arthritis and axial spondyloarthritis with traditional biologic and non-biologic DMARDs. Best Practice and Research in Clinical Rheumatology, 2014, 28, 793-806.	3.3	8
123	Laparoscopic Colorectal Resections. Diseases of the Colon and Rectum, 2014, 57, 869-874.	1.3	29
124	Are There Clinical Differences in Limited Systemic Sclerosis according to Extension of Skin Involvement?. International Journal of Rheumatology, 2014, 2014, 1-5.	1.6	2
125	Altered lipidome and antioxidative activity of small, dense HDL in normolipidemic rheumatoid arthritis: Relevance of inflammation. Atherosclerosis, 2014, 237, 652-660.	0.8	47
126	Drug Therapies for Peripheral Joint Disease in Psoriatic Arthritis: A Systematic Review. Journal of Rheumatology, 2014, 41, 2277-2285.	2.0	51

#	Article	IF	Citations
127	Incidence and prevalence of lupus in Buenos Aires, Argentina: a 11-year health management organisation-based study. Lupus Science and Medicine, 2014, 1, e000021.	2.7	31
128	Remission criteria and activity indices in psoriatic arthritis. Clinical Rheumatology, 2014, 33, 1323-1330.	2.2	42
129	Patient Preferences for Biologic Agents in Rheumatoid Arthritis: A Discrete-Choice Experiment. Value in Health, 2013, 16, 385-393.	0.3	71
130	Validation in Spanish of a screening questionnaire for the detection of psoriatic arthritis in patients with psoriasis. Rheumatology, 2013, 52, 510-514.	1.9	18
131	Validation of a Prediction Rule for the Diagnosis of Rheumatoid Arthritis in Patients with Recent Onset Undifferentiated Arthritis. International Journal of Rheumatology, 2013, 2013, 1-6.	1.6	7
132	Incidence and Prevalence of Polymyositis and Dermatomyositis in a Health Management Organization in Buenos Aires. Journal of Clinical Rheumatology, 2013, 19, 303-307.	0.9	27
133	Prevalence and Correlates of Metabolic Syndrome in Patients With Rheumatoid Arthritis in Argentina. Journal of Clinical Rheumatology, 2013, 19, 439-443.	0.9	19
134	The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Annals of the Rheumatic Diseases, 2013, 72, 986-991.	0.9	240
135	Treatment of Early Rheumatoid Arthritis in a Multinational Inception Cohort of Latin American Patients. Journal of Clinical Rheumatology, 2012, 18, 327-335.	0.9	41
136	Anti-malarials exert a protective effect while Mestizo patients are at increased risk of developing SLE renal disease: data from a Latin-American cohort. Rheumatology, 2012, 51, 1293-1298.	1.9	46
137	Body Surface Area. Diseases of the Colon and Rectum, 2012, 55, 1153-1159.	1.3	21
138	Critical Appraisal of the Guidelines for the Management of Ankylosing Spondylitis: Disease-Modifying Antirheumatic Drugs. American Journal of the Medical Sciences, 2012, 343, 357-359.	1.1	5
139	Ultrasound assessment of new onset bilateral painful shoulder in patients with polymyalgia rheumatica and rheumatoid arthritis. Clinical Rheumatology, 2012, 31, 1383-1387.	2.2	42
140	The Actual Role of Therapy with Traditional Disease-modifying Antirheumatic Drugs in Psoriatic Arthritis. Journal of rheumatology Supplement, The, 2012, 89, 67-70.	2.2	17
141	Cost of rheumatoid arthritis in a selected population from Argentina in the prebiologic therapy era. ClinicoEconomics and Outcomes Research, 2012, 4, 219.	1.9	2
142	Early rheumatoid arthritis in Latin America: Low socioeconomic status related to high disease activity at baseline. Arthritis Care and Research, 2012, 64, 1135-1143.	3.4	65
143	Patient Considerations in the Management of Rheumatoid Arthritis: Role of Once-A-Month Golimumab Injection. Clinical Medicine Insights Therapeutics, 2011, 3, CMT.S3574.	0.4	O
144	CONVENTIONAL THERAPY OF PSORIATIC ARTHRITIS: EVIDENCE-BASED REVIEW. Reumatismo, 2011, 59, 81-4.	0.9	0

#	Article	IF	CITATIONS
145	Incidence and Prevalence of Systemic Sclerosis in a Healthcare Plan in Buenos Aires. Journal of Clinical Rheumatology, 2011, 17, 59-63.	0.9	32
146	Cost-effectiveness of a hypertension management programme in an elderly population: a Markov model. Cost Effectiveness and Resource Allocation, $2011, 9, 4$.	1.5	15
147	Incidence and prevalence of psoriatic arthritis in Buenos Aires, Argentina: a 6-year health management organization-based study. Rheumatology, 2011, 50, 729-734.	1.9	62
148	Incidence of multiple sclerosis in Buenos Aires: a 16â€year health maintenance organizationâ€based study. European Journal of Neurology, 2010, 17, 479-482.	3.3	18
149	Prefilled certolizumab pegol (Cimzia®) syringes for self-use in the treatment of rheumatoid arthritis. Medical Devices: Evidence and Research, 2010, 3, 25.	0.8	3
150	BL2 PATIENT PREFERENCES FOR BIOLOGIC AGENTS IN RHEUMATOID ARTHRITIS: A DISCRETE CHOICE EXPERIMENT. Value in Health, 2010, 13, A243.	0.3	0
151	Treatment guidelines for psoriatic arthritis. International Journal of Clinical Rheumatology, 2009, 4, 329-342.	0.3	5
152	Metabolic syndrome in Argentinean patients with systemic lupus erythematosus. Lupus, 2009, 18, 1019-1025.	1.6	62
153	Update on the treatment of peripheral arthritis in psoriatic arthritis. Current Rheumatology Reports, 2009, 11, 270-277.	4.7	14
154	A case of primary erythromelalgia. Journal of the European Academy of Dermatology and Venereology, 2009, 23, 1338-1339.	2.4	4
155	Treatment recommendations for psoriatic arthritis. Annals of the Rheumatic Diseases, 2009, 68, 1387-1394.	0.9	483
156	Management of Patients With Rheumatoid Arthritis in Latin America. Journal of Clinical Rheumatology, 2009, 15, 203-210.	0.9	44
157	Childhood systemic lupus erythematosus in Latin America. The GLADEL experience in 230 children. Lupus, 2008, 17, 596-604.	1.6	108
158	Use of rituximab for the treatment of rheumatoid arthritis: the Latin American context. Rheumatology, 2008, 47, 1097-1099.	1.9	18
159	Consensus on a core set of domains for psoriatic arthritis. Journal of Rheumatology, 2007, 34, 1167-70.	2.0	155
160	Effect of Education on Blood Pressure Control in Elderly PersonsA Randomized Controlled Trial. American Journal of Hypertension, 2006, 19, 737-743.	2.0	36
161	Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. Journal of Rheumatology, 2006, 33, 1422-30.	2.0	87
162	Initial Application for Investigational Device Exemption (IDE). The Neuroradiology Journal, 2005, 18, 79-86.	0.1	0

#	ARTICLE	IF	CITATIONS
163	Gait disorders are associated with non-cardiovascular falls in elderly people: a preliminary study. BMC Geriatrics, 2005, 5, 15.	2.7	27
164	Gait Velocity as a Single Predictor of Adverse Events in Healthy Seniors Aged 75 Years and Older. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2005, 60, 1304-1309.	3.6	563
165	The GLADEL Multinational Latin American Prospective Inception Cohort of 1,214 Patients With Systemic Lupus Erythematosus. Medicine (United States), 2004, 83, 1-17.	1.0	372
166	Re: Guidelines for the diagnosis and management of PMR/GCA. Age and Ageing, 2004, 33, 210-a-211.	1.6	0
167	Consultations for work related low back pain in Argentina. Journal of Rheumatology, 2002, 29, 1029-33.	2.0	9
168	Inflammatory muscle disease: therapeutic aspects. Best Practice and Research in Clinical Rheumatology, 2000, 14, 55-71.	3.3	2
169	Synovial tissue responses following treatment of rheumatoid arthritis with the humanized monoclonal antibody CAMPATH-1H. Arthritis and Rheumatism, 1996, 39, 181-182.	6.7	4
170	FREQUENCY OF AUTOANTIBODIES TO A MAJOR EPITOPE ON THE CARBOXYL TERMINAL FRAGMENT OF CENP-B IN PATIENTS WITH AUTOIMMUNE DISEASE. Rheumatology, 1995, 34, 407-412.	1.9	14
171	Frequency and clinical associations of anti-chromo antibodies in connective tissue disease Annals of the Rheumatic Diseases, 1994, 53, 666-670.	0.9	6
172	Systemic Lupus Erythematosus and Amyloidosis. Arthritis and Rheumatism, 1979, 22, 554-556.	6.7	31
173	Cambios en la funci \tilde{A}^3 n endotelial vascular de pacientes con artritis reumatoidea en tratamiento. Global Rheumatology, 0, , .	0.0	0
174	Evaluaci \tilde{A}^3 n de las necesidades educativas en pacientes con osteoartritis de rodilla en una cohorte latinoamericana. Global Rheumatology, 0, , .	0.0	0